Contraindications after using tocilizumab

Tocilizumab is a monoclonal antibody drug targeting the interleukin-6 (IL-6) receptor. It is commonly used to treat rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis, and cytokine storms caused by new coronavirus infection. However, because its mechanism directly interferes with the immune pathway, there are certain contraindications after using tocilizumab, which requires special attention during clinical use. Especially after stopping the drug or interrupting the treatment, the monitoring of side effects and secondary reactions should be strengthened.

First, the risk of infection is one of the main concerns after the use of tocilizumab. The drug reduces the inflammatory response by inhibiting the IL-6 signaling pathway, but also suppresses normal immune function. Even after the drug is discontinued, its immunosuppressive effects may continue for several weeks, leaving patients vulnerable to opportunistic infections such as tuberculosis, fungi, and herpes zoster. Therefore, for a period of time after stopping the drug, patients should avoid going to crowded places, keep wounds clean, and avoid contact with people at risk of infection.

Secondly, liver function abnormalities and neutropenia may also develop gradually after discontinuation of tocilizumab. This is because tocilizumab may cause a certain burden on liver cells during the metabolic process, and its inhibitory effect on bone marrow may also continue to affect the hematopoietic system. Therefore, liver enzymes and blood routine indicators should be continuously monitored, and the blood test frequency should be maintained once a month even after the end of treatment.

In addition, some patients may experience disease rebound effects after discontinuation of tocilizumab, especially patients with rheumatoid arthritis. This rebound phenomenon may manifest as increased joint swelling, prolonged morning stiffness, or even fever. Therefore, doctors need to reasonably arrange the rhythm of drug withdrawal based on the patient's symptoms, and use glucocorticoids for transitional treatment when necessary.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html